Algernon Pharmaceuticals Selects NP-120 (Ifenprodil) for its Lead Phase 2 Trial for Idiopathic Pulmonary Fibrosis and Chronic Cough Pharmaceutical Investing
Life Science Big News Roundup: Algernon’s NP-120 Outperforms Merck’s Phase 3 Drug MK-7264 by 110 Percent; Naturally Splendid’s Natera Sport(TM) Bites at Genesis PGA Tournament Life Science Investing
Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110 Percent Biotech Investing
